78 268

Cited 0 times in

Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers: a retrospective cohort study using a Korean clinical research database

Authors
Park, I; Sheen, SS; Lim, HS; Yoon, D; Park, MY; Lee, SH; Shin, GT; Kim, H; Park, RW
Citation
American journal of cardiovascular drugs : drugs, devices, and other interventions, 12(4):255-262, 2012
Journal Title
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN
1175-32771179-187X
Abstract
BACKGROUND AND AIM: Clinical use of angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) is associated with hyperkalemia as an adverse drug reaction. Although it has significant clinical implications, the incidence and relative risks of hyperkalemia with various ARBs have not yet been fully evaluated. The purpose of this study was to determine the risk of hyperkalemic events in hospitalized patients treated with different ARBs and to compare the risk among them.



METHODS: We constructed a retrospective cohort composed of hospitalized adult patients who took ARBs in a single tertiary teaching hospital between April 2004 and March 2010. We estimated the incidence of hyperkalemia (serum potassium level >5.5 mEq/L) with various ARBs, and then compared the risk between them using a multivariate Cox proportional hazard model based on age, sex, Charlson co-morbidity score, baseline serum potassium, underlying diseases, and concomitant drugs.



RESULTS: We identified 6992 evaluable intervals from 5449 patients treated with one of the seven ARBs during hospitalization over the 71-month study period with 2521.6 patient-months. We found 381 hyperkalemic events (5.4%) during the study period and an overall event rate of 15.1/100 patient-months. Moderate to fatal hyperkalemia was relatively rare (>6.0 mEq/L, 2.1% [moderate]; >6.5 mEq/L, 0.9% [severe]; >7.0 mEq/L, 0.3% [fatal]). After adjustment for covariates, telmisartan showed a lower risk of hyperkalemia (hazard ratio 0.67; 95% confidence interval 0.51, 0.89) compared with all other ARBs.



CONCLUSION: The risk of hyperkalemic events in hospitalized patients treated with different ARBs was defined. Telmisartan showed a relatively lower hyperkalemic risk profile in hospitalized patients compared with other ARBs.
MeSH terms
AdultAgedAngiotensin Receptor Antagonists/*adverse effectsBiomedical ResearchCohort StudiesDatabases, FactualDatabases, PharmaceuticalFemaleHospitalizationHumansHyperkalemia/*chemically inducedKoreaMaleMiddle AgedPPAR gamma/drug effectsProportional Hazards ModelsRetrospective StudiesRisk
DOI
10.2165/11634470-000000000-00000
PMID
22799614
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Medical Informatics
Journal Papers > School of Medicine / Graduate School of Medicine > Nephrology
Journal Papers > School of Medicine / Graduate School of Medicine > Pulmonary & Critical Care Medicine
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
AJOU Authors
박, 인휘신, 승수임, 홍석신, 규태김, 흥수박, 래웅
Files in This Item:
fulltext not available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse